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SUMMARY
Objective: To evaluate and compare the efficacy of topical antifungal drugs applied to 
the treatment of each dermatomycosis. Methods: A systematic review of randomized 
clinical trials, published in Portuguese, Spanish and English until July 2010, which com-
pared the use of azole and allylamine antifungal drugs among themselves and with pla-
cebo in the treatment of cutaneous candidiasis and T. versicolor, T. pedis, T. cruris and 
T. corporis was performed. The efficacy outcomes evaluated were mycological cure at 
the end of treatment and sustained cure. Results: Of the 4,424 studies initially identi-
fied, 49 met the selection criteria and were included in the meta-analyses. The grouped 
efficacy data evidenced the superiority of antifungal drugs compared to placebo, regard-
less of the dermatomycosis under evaluation, with odds ratio values ranging from 2.05 
(95% CI; 1.18-3.54) to 67.53 (95% CI; 11.43-398.86). Allylamines were better than azoles 
only for the outcome of sustained cure (OR 0.52 [95% CI; 0.31-0.89]). Conclusion: There 
is consistent evidence of the superiority of antifungal drugs over the use of placebo, and 
placebo-controlled studies are no longer justifiable. Allylamines maintain the mycologi-
cal cure for longer periods compared to azole drugs. Given the significant cost difference 
among the classes, pharmacoeconomic analyses should be performed.
Keywords: Dermatomycoses; antimycotic drugs; meta-analysis; topical administration.
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INTRODUCTION
Dermatomycoses are the most widespread superficial fun-
gal infections among human beings, being an important 
cause for morbidity. Although they rarely present risk to 
the life of patients, they may result in debilitating effects, 
affecting their quality of life1-3. 
The incidence of these diseases is increasing due to the 
higher number of immunocompromised patients and of 
recreation spaces, in which swimming pools and other 
fomites are shared3. The most frequent diseases are der-
matophytoses or tineas (ringworms) infections resulting 
from fungi affecting the keratinized tissues of the skin, 
hair, and nails. Skin commensal yeasts, such as Malasse-
zia furfur and Candida spp., are also important causative 
agents of dermatomycoses4.
The diagnosis of these diseases is based on the combi-
nation of clinical and laboratory data. Clinical diagnosis 
should include physical examination of lesions and epide-
miological history, while mycological diagnosis is mainly 
based on microorganism visualization in direct micros-
copy and growth in culture4-6. 
The treatment of these infections is different from that 
used in systemic infections, consisting in the primary use 
of antifungal topical formulations7-8, which are sold over 
the counter in Brazil9.
Given the shortage of systematic and quantitative re-
view studies related to the treatment of dermatomycoses 
with topical antifungal drugs,  and given that those already 
published are limited to the treatment of Tinea pedis10,11, 
a quantitative systematic review was performed to deter-
mine the efficacy of topical antifungal drugs in the treat-
ment of each dermatomycosis and to establish possible dif-
ferences among pharmacological classes.
METHODS
SEARCH STRATEGY AND SELECTION CRITERIA
The research was conducted based on the recommenda-
tions of the Cochrane Collaboration for systematic reviews 
and meta-analyses12. A wide spectrum of strategies was 
used in the search for randomized clinical trials (RCT), 
and the descriptors were the names of azoles and allyl-
amine antifungal drugs of interest (bifonazole, ketocon-
azole, clotrimazole, econazole, fenticonazole, flutrimazole, 
isoconazole, miconazole, naftifine, oxiconazole, sertacon-
azole, terbinafine, and tioconazole). The terms “vaginal”, 
“vulvovaginal”, and “oropharyngeal” were included in the 
search preceded by the Boolean term “NOT”, and only 
studies that evaluated the topical use of these drugs were 
selected. 
The search was performed in the MEDLINE, Cochrane 
Central Register of Controlled Trials, Embase, LILACS, 
and International Pharmaceutical Abstracts (IPA) data-
bases, and included studies published up July 2010, in Por-
tuguese, Spanish or English, which compared the use of 
topical antifungal drugs in treatment of dermatomycoses 
among themselves or with a placebo. Studies that did not 
restrict their evaluation scope to single type of dermato-
mycosis were excluded, including patients diagnosed with 
dermatophytoses or dermatomycoses in general. Further-
more, studies evaluating onychomycosis were excluded 
because this disease presents a very distinct pattern of 
treatment duration due to its chronic status.
The intervention consisted in any azole or allylamine 
topical antifungal drug, regardless of the dosage form, 
concentration, therapeutic regimen, and duration of the 
treatment. In each study, the clinical diagnosis for der-
matomycosis should have been mycologically confirmed 
through the direct microscopy and/or fungal growth in 
culture technique.
The initial selection of studies, based on the evaluation 
of the title and summary, was performed by two indepen-
dent proofreaders (IR and AS). Any discrepancy was re-
solved in a consensus meeting and, when necessary, in the 
presence of a third proofreader (CC).
DATA EXTRACTION AND QUALITY ASSESSMENT
The extraction of data from the selected studies was per-
formed by the same independent proofreaders (IR and 
AS). The collected data consisted of patients’ basic char-
acteristics, evaluated dermatomycosis, interventions and 
controls, therapeutic regimen used, and efficacy data. 
The efficacy results evaluated were mycological cure 
at the end of treatment, which included results of cure 
obtained at the end of the treatment, or up to seven days 
after its conclusion; and sustained cure, which included 
results of cure obtained after the treatment period, with 
a 14-day minimal interval without administration of the 
studied medications. In cases where more than one result 
of sustained cure was described, the one with the longest 
follow-up period was prioritized. For both efficacy results, 
the cure was confirmed through microscopy and/or cul-
ture. The clinical cure rate, due to its subjective nature, was 
not considered, and studies that only reported this result 
were excluded. Studies that only evaluated patients with 
T. cruris were added to those that included patients with 
diagnosis of T. cruris and T. corporis.
The methodological quality of each selected study was 
assessed through the scale of Jadad et al.13, which takes 
into account aspects related to the randomization, blind-
ing, losses, and withdrawals. Only studies that presented 
a minimum score of 3 were included. To assess the risk of 
bias, a tool made available by The Cochrane Collaboration, 
that analyzes the study in six domains, considering the fol-
lowing biases: selection, performance, detection, attrition, 
publication bias and other sources of biases, was used12. 
Thus, only good quality controlled and randomized clini-
cal trials were included in the analyses, with evidence level 
1a and grade of recommendation A14.
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STATISTICAL ANALYSES
For the efficacy results analyzed, the random effect model 
and inverse variance method was used to interpolate in-
dividual odds ratio (OR) results of the studies. The results 
were also expressed in absolute risk (AR), absolute risk re-
duction (ARR), and number needed to treat (NNT).
The existing heterogeneity among the selected studies 
was assessed through the inconsistency index (I2), provid-
ed that an amount higher than 50% is indicative of high 
heterogeneity. In these cases, sensitivity analyses were con-
ducted in order to identify whether the individual charac-
teristics of each study could have influenced the results. 
Therefore, each study was hypothetically removed from 
the meta-analysis and its influence on the global result as-
sessed. All analyses were performed through the software 
Review Manager 5.V.1.
RESULTS 
SYSTEMATIC REVIEW
4,424 articles were retrieved, of which 4,183 were excluded 
after title and/or summary evaluation, and 95 after full 
evaluation. The main reasons that resulted in exclusion 
were noncompliance with the quality criteria proposed by 
Jadad, and the fact that many of them did not restrict their 
evaluation to a single type of dermatomycosis. Additional-
ly, 97 were excluded because they were duplicated. Hence, 
49 studies met the eligibility criteria and were included in 
the meta-analyses. Of these, data from 57 comparisons 
were extracted in a universe of 6,044 recruited patients. 
With respect to the basic characteristics of these patients, 
the weighted average age was 39.2 years, and 69.6% were 
male. 
Tables 1 and 2 describe the characteristics of the stud-
ies included in the meta-analyses.
  
CRITICAL QUALITY ASSESSMENT
Only medium to high quality studies were included, pur-
suant to the criteria of Jadad et al.13; an average score of 
3.4 was found in the studies. In most studies selected, the 
information available in the articles related to the method 
used to generate the randomization sequence and allo-
cation concealment was insufficient. However, the basic 
characteristics of the patients allocated to each group were 
homogenous, suggesting that the attribution of moderate 
risk of bias for this domain did not affect the reliability of 
the results found. 
EFFICACY RESULTS BY EVALUATED DERMATOMYCOSIS
CUTANEOUS CANDIDIASIS
Five studies were retrieved, which resulted in a total of 383 
patients and six comparisons between topical antifungal 
drugs and placebo in the treatment of cutaneous candidia-
sis. Of these comparisons, four were established between 
placebo and the azoles miconazole 2%, clotrimazole 1%, ec-
onazole 1%, and bifonazole 1%, with a treatment period of 
14 to 28 days. In the other two, the allylamine naftifine 1% 
was compared to placebo, with a 21-day treatment period. 
For the outcome of mycological cure at the end of 
treatment, both meta-analyses results favored antifungal 
drugs. OR values of 10.06 (95% CI; 3.01-33.64), AR of 
75%, ARR of 48%, and NNT of 2 were found in favor of 
the azoles and OR values of 67.53 (95% CI; 11.43-398.86), 
AR of 88%, ARR of 78%, and NNT of 1 favoring the al-
lylamines when compared to placebo. 
The I2 of 35% found in the comparison established be-
tween azoles and placebo indicates the existence of mod-
erate heterogeneity among the included results, being 
high (I2 = 52%) between the studies selected to integrate 
the meta-analysis comparing allylamines and placebo. 
Although a high heterogeneity was found between the 
two included studies, they showed similar results favor-
ing naftifine.
Only studies comparing naftifine with placebo 
showed results of sustained cure, and OR values of 37.14 
(95% CI; 13.08-105.45), AR of 83%, ARR of 71%, and 
NNT of 1, favoring the use of allylamine. The hetero-
geneity was null among the selected studies (I2 = 0%). 
The follow-up period was of two weeks after the end of 
therapy.
T. VERSICOLOR
Ten placebo-controlled studies, totaling 798 patients, eval-
uated the treatment of T. versicolor. Of these studies, data 
from eight comparisons established between placebo and 
the azoles clotrimazole 1%, bifonazole 1%, miconazole 
2%, ketoconazole 2%, and econazole 1% were extracted, 
with a treatment period varying from two days, using the 
shampoo dosage form, to 28 days. Another four studies 
compared naftifine and terbinafibe, both at 1%, with pla-
cebo over treatment periods from seven to 28 days.
For the outcome of mycological cure at the end 
of treatment, the interpolation of six studies compar-
ing azoles with placebo resulted in an OR of 20.11 
(95% CI; 9.07-44.59), AR of 89%, ARR of 54%, and NNT 
of 2, favoring antifungal drugs. When grouping the results 
of three studies comparing allylamines with placebo, the 
OR value obtained was 2.05 (95% CI; 1.18-3.54), AR of 
47%, ARR of 17%, and NNT of 6, favoring allylamines. 
The inconsistency index observed among the interpolated 
studies was null (I2 = 0%) or low (I2 = 23%).  
For the outcome of sustained cure, the combined 
data from seven studies comparing azoles with placebo 
resulted in an OR of 12.61 (95% CI; 5.23-30.41), AR of 
83%, ARR of 59%, and NNT of 2, favoring azoles. The 
value of I2 was 30% indicating moderate heterogeneity 
among the studies. The follow-up period was from two 
to six weeks after the end of the therapy. The grouping of 
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Table 1 – Characteristics of the studies included in the meta-analyses: azole and allylamine drugs versus placebo
Author, year Jadadscore
n 
total
Dermatomycosis
evaluated Intervention Dosage form
Therapeutic
regimen
Duration 
of the 
treatment 
(days)
Total follow-
up period
(days)
Assessed 
outcomes
(Cure)
Astorga, 198915 4 59 Candidiasis Naftiﬁne 1% Cream Twice a day 21 35 Mic/Sust
Bagatell, 1991a16 3 88 T. pedis Naftiﬁne 1% Cream Twice a day 28 42 Mic/Sust
Bagatell, 1991b16 3 228 T. pedis Naftiﬁne 1% Cream Twice a day 28 42 Mic/Sust
Berman, 199217 3 165 T. pedis Terbinaﬁne 1% Cream Twice a day 7 42 Mic/Sust
Budimulja, 200118 3 120 T. cruris and T. corporis Terbinaﬁne 1% Cream Once a day 7 56 Sustained
Cullen, 197719 3 30 Candidiasis Miconazole 2% Lotion Twice a day 14 28 Mycological
Cullen, 1984a20 3 26 Candidiasis Clotrimazole 1% Cream Twice a day 14 to 21 42 to 49 Mycological
Cullen, 1984b20 3 23 Candidiasis Econazole 1% Cream Twice a day 14 to 21 42 to 49 Mycological
Daily, 198521 3 91 T. pedis Econazole 1% Cream Twice a day 28 to 42 56 to 70 Mic/Sust
Duncan, 197522 3 150 T. pedis Miconazole 2% Cream Twice a day 28 56 Mic/Sust
Ellis, 1989a23 4 178 T. pedis Oxiconazole 1% Cream Once a day 28 42 Mic/Sust
Ellis, 1989b23 4 179 T. pedis Oxiconazole 1% Cream Twice a day 28 42 Mic/Sust
Evans, 199124 3 86 T. pedis Terbinaﬁne 1% Cream Once a day 14 42 Mic/Sust
Evans, 199225 3 76 T. cruris and T. corporis Terbinaﬁne 1% Cream Once a day 7 28 Mic/Sust
Faergemann, 199726 3 61 T. versicolor Terbinaﬁne 1% Emulsion – gel Once a day 7 56 Mic/Sust
Gentles, 197527 4 56 T. pedis Miconazole 2%Miconazole 1%
Cream
Powder
Once a day
Twice a day 28 28 Mycological
Greer, 199028 3 23 T. cruris Terbinaﬁne 1% Cream Twice a day 14 28 Mic/Sust
Hollmen, 200229 3 101 T. pedis Terbinaﬁne 1% Emulsion – gel Once a day 7 56 Sustained
James, 2007a30 4 56 T. pedis Terbinaﬁne 1% Emulsion – gel Once a day 5 42 Mic/Sust
James, 2007b30 4 55 T. pedis Terbinaﬁne 3% Emulsion – gel Once a day 5 42 Mic/Sust
Korting, 200131 3 100 T. pedis Terbinaﬁne 1% Cream Once a day 7 56 Sustained
Lalosevic, 1984a32 4 129 Candidiasis Bifonazole 1% Cream Once a day 28 42 Mycological
Lalosevic, 1984b32 4 134 Candidiasis Bifonazole 1% Cream Twice a day 28 42 Mycological
Lebwohl, 2001a33 4 153 T. pedis Terbinaﬁne 1% Solution Twice a day 7 56 Mycological
Lebwohl, 2001b33 4 66 T. cruris and T. corporis Terbinaﬁne 1% Solution Once a day 7 28 Mycological
Millikan, 199034 3 30 T. cruris Terbinaﬁne 1% Cream Twice a day 14 28
Montoya, 1985a35 3 48 T. versicolor Clotrimazole 1% Cream Twice a day 28 42 Mic/Sust
Montoya, 1985b35 3 44 T. versicolor Naftiﬁne 1% Cream Twice a day 28 42 Mic/Sust
Mora, 198436 4 43 T. versicolor Bifonazole 1% Cream Once a day 14 28 Mic/Sust
Ortiz, 1978a37 3 100 T. pedis Miconazole 2% Cream Twice a day 28 56 Mycological
Ortiz, 1978b37 3 50 T. versicolor Miconazole 2% Cream Twice a day 14 28 Mic/Sust
Ortonne, 200638 3 324 T. pedis Terbinaﬁne 1% FFS* Single dose – – Sustained
Quiñones, 1980a39 3 41 T. versicolor Miconazole 2% Cream Once a day 14 28 Sustained
Quiñones, 1980b39 3 51 T. versicolor Econazole 1% Cream Once a day 14 28 Sustained
Savin, 198640 3 101 T. versicolor Ketoconazole 2% Cream Once a day 14 56 Mic/Sust
Savin, 199041 3 27 T. pedis Terbinaﬁne 1% Cream Twice a day 28 42 Mic/Sust
Savin, 199942 3 152 T. versicolor Terbinaﬁne 1% Solution Twice a day 7 56 Mic/Sust
Savin, 200643 3 588 T. pedis Sertaconazole 2% Cream Twice a day 28 42 Mic/Sust
Segal, 1999a44 4 20 T. versicolor Bifonazole 1% Shampoo Once a day 2 42 Mic/Sust
Segal, 1999b44 4 20 T. versicolor Bifonazole 1% Shampoo Once a day 7 42 Mic/Sust
Smith, 197745 4 82 T. pedis Clotrimazole 1% Solution Twice a day 28 to 42 28 to 42 Mycological
Smith, 1990a46 3 23 T. pedis Terbinaﬁne 1% Cream Twice a day 28 42 Mic/Sust
Syed, 200047 4 40 T. pedis Terbinaﬁne 1% Cream Once a day 10 308 Mic/Sust
Van Heerden, 199748 3 83 T. cruris and T. corporis Terbinaﬁne 1% Emulsion – gel Once a day 7 56 Mic/Sust
Vermeer, 199749 3 115 T. versicolor Terbinaﬁne 1% Solution Twice a day 7 56 Sustained
Vicik, 198450 4 148 T. versicolor Econazole 1% Cream Once a day 14 to 21 14 to 21 Mycological
Zaias, 198851 3 60 Candidiasis Naftiﬁne 1% Cream Twice a day 21 35 Mic/Sust
FFS, ﬁlm forming solution; Mic, mycological; Sust, sustained.
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Table 2 – Characteristics of the studies included in the meta-analyses: allylamines versus azoles
Author, 
year
Jadad
Score
n total
Dermatomycosis
evaluated
Intervention 
1
Duration of 
the
treatment
(days)
Total 
follow-up
period
(days)
Intervention 
2
Duration 
of the
treatment
(days)
Total 
follow-up
period
(days)
Evaluated
outcomes
(Cure)
Ablon, 
1996a52
3
66
T. pedis
Terbinaﬁne 
cream 1% 
once a day
14
42 to 
70
Oxiconazole 
lotion 1% 
once a day
14 42 to 70 Mic/Sust
Ablon, 
1996b52
3
66
T. pedis
Naftiﬁne cream
1% once a day
14
42 to 
70
Oxiconazole 
lotion 1% 
once a day
14 42 to 70 Mic/Sust
Aste, 
199153
3
40
T. versicolor
Terbinaﬁne 
cream 1% 
twice a day
22 36
Bifonazole 
cream 
1% twice a day
26
40
Mycological
Bergstresser, 
199354
3
193
T. pedis
Terbinaﬁne 
cream 1% 
twice a day
7 84
Clotrimazole 
cream 1% 
twice a day
28 84 Sustained
Budimulja, 
199855
4
185
T. cruris
Terbinaﬁne 
cream 1% 
once a day
7 56
Bifonazole 
cream 
1% once a day
21 56 Mic/Sust
Evans, 
199356
5
256
T. pedis
Terbinaﬁne 
cream 1% 
twice a day
7 42
Clotrimazole 
cream 1% 
twice a day
28 42 Mic/Sust
Irvine, 
199057
5 57 T. pedis
Naftiﬁne cream 
1% twice a day
28 to
42
28 to 
42
Clotrimazole 
cream 1% 
twice a day
28 to 42 28 to 42 Mycological
Leenutaphong,
199958
3
48
T. pedis
Terbinaﬁne 
cream 1% 
once a day
7 70
Miconazole 
cream 2% 
twice a day
28 70 Mic/Sust
Millikan, 
198859
4 126
T. cruris and T. 
corporis
Naftiﬁne cream 
1% twice a day
28 42
Econazole 
cream 1% 
twice a day
28 42 Mic/Sust
Montoya, 
1985c35
3 48 T. versicolor
Naftiﬁne cream 
1% twice a day
28 42
Clotrimazole 
cream 1% 
twice a day
28 42 Mic/Sust
Sanchez- Carazo,
199460
3
43
T. pedis
Terbinaﬁne 
cream 1% 
once a day
28 42
Bifonazole 
cream 
1%
once a day
28 42 Mic/Sust
Schopf, 
199961
4
699
T. pedis
Terbinaﬁne 
solution 1% 
twice a day
7 56
Clotrimazole 
solution 1% 
twice a day
28 56 Mic/Sust
Smith,
1990b(1)62
3
160
T. pedis
Naftiﬁne cream 
1% once a day
28 42
Clotrimazole 
cream 1%
 twice a day
28 42 Mic/Sust
Smith, 
1990b(2)62
3
121
T. pedis
Naftiﬁne cream 
1% twice a day
28 42
Clotrimazole 
cream 1% 
twice a day
28 42 Mic/Sust
Wahid, 
199763
3
87
T. pedis
Terbinaﬁne 
cream 1% 
once a day
14 56
Bifonazole 
cream 
1%
once a day
14 56
Sustained
Mic, mycological; Sust, sustained.
four studies comparing allylamines with placebo showed 
an OR of 6.07 (95% CI; 2.19-16.86), AR of 75%, ARR 
of 45%, and NNT of 2, favoring allylamine drugs. High 
heterogeneity among the included studies was detected 
(I2 = 74%). However, after the hypothetical removal of the 
meta-analysis by Montoya35, responsible for the high het-
erogeneity, the amount of I2 decreased to zero and the effi-
cacy result remained statistically favorable to allylamines. 
The follow-up period was from two to seven weeks after 
the end of the treatment.
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T. PEDIS
Nineteen studies were found, in which 1,937 patients were 
recruited, comparing azole and allylamine antifungal 
drugs with placebo to treat T. pedis, being, therefore, the 
most evaluated dermatomycosis. Of these, seven studies 
compared the azoles econazole 1%, miconazole 2%, oxi-
conazole 1%, sertaconazole 2%, and clotrimazole 1% with 
placebo, with atreatment period of 28 to 42 days. The 12 
remaining studies compared the allylamines naftifine 1% 
and terbinafine 1% and 3% with placebo, with a treatment 
period varying from one day, in case of film forming solu-
tion, which requires a single dose, up to 28 days.
For the outcome of mycological cure at the end of 
treatment, azoles and allylamines showed superiority 
when compared to placebo. The grouping of seven studies 
comparing azoles with placebo resulted in an OR of 5.54 
(95% CI; 3.01-10.19), AR of 72%, ARR of 36%, and NNT 
of 3, with value of I2 of 71%, indicating high heterogene-
ity among the included studies. With the hypothetical re-
moval of the study by Ortiz37 from the meta-analysis, the 
value of I2 became null and the result remained statisti-
cally favorable to azoles. When nine studies comparing al-
lylamines with placebo were interpolated, an OR of 5.87 
(95% CI; 2.46-14.01), AR of 63%, ARR of 35%, and NNT 
of 3 were obtained, with a value of I2 of 81%. With the hy-
pothetical withdrawal of the studies identified as respon-
sible for the high heterogeneity from the meta-analysis, 
the value of I2 decreased and the result remained favorable 
to allylamines.
Azoles and allylamines were also better than pla-
cebo in the outcome of sustained cure; an OR of 6.64 
(95% CI; 4.65-9.48), AR of 73%, ARR of 44%, and NNT 
of 2 was found when four studies comparing azoles with 
placebo were grouped, with follow-up period of two to 
four weeks after the end of the therapy. When grouping 11 
studies comparing allylamines with placebo, with follow-
up period of two to 12 weeks after the end of the treatment, 
an OR of 14.22 (95% CI; 9.49-21.32), AR of 78%, ARR 
of 56%, and NNT of 2 were obtained. The inconsistency 
index observed among the interpolated studies was null 
(I2 = 0%) or low (I2 = 23%).  
T. CRURIS AND T. CORPORIS
On the evaluation of the treatment of T. cruris and T. cor-
poris, six studies were retrieved, totalling 298 patients, all 
comparing terbinafine 1% with placebo, with a short peri-
od of treatment, from seven to 14 days, and follow-up pe-
riod from two to seven weeks after the end of the therapy.
For the outcome of mycological cure at the end of 
treatment, the grouping of five studies resulted in an OR of 
6.40 (95% CI; 2.64-15.49), an AR of 48%, ARR of 33%, and 
NNT of 3. The I2 found was 6%. For the outcome sustained 
cure, the sum of the data from five studies resulted in an 
OR of 14.43 (95% CI; 7.62-27.33), AR of 85%, ARR of 58%, 
and NNT of 2, with a null value of I2; therefore, terbinafine 
was superior to placebo in both analyzed outcomes.
EFFICACY RESULTS OF AZOLES VERSUS ALLYLAMINES
Fourteen studies comparing azoles to allylamine drugs in 
the treatment of dermatomycoses were retreived. Of these, 
ten evaluated patients were diagnosed with T. pedis, two 
with T. versicolor, and two with T. cruris and T. corporis. 
Figure 1 shows the results of the meta-analyses of azoles 
versus allylamines for each dermatomycosis evaluated.
For the outcome of mycological cure at the end of 
treatment, eight studies comparing the azoles oxiconazole 
1%, clotrimazole 1%, miconazole 2%, and bifonazole 1% 
with naftifine and terbinafine, both at 1%, in the treat-
ment of T. pedis were grouped. The value of OR ob-
tained was statistically favorable to the use of allylamines 
(0.55 [95% CI; 0.33-0.92]), with AR of 78%, ARR of 2%, 
and NNT of 41. The I2 value of 33% indicates moderate 
heterogeneity among the selected studies, validating the 
quality of the evidence found. 
For the same outcome, when two studies compar-
ing bifonazole and clotrimazole with terbinafine and 
naftifine, all at 1%, in the treatment of T. versicolor were 
grouped, a non-statistically significant OR value of 2.25 
(95% CI; 0.09-53.79) was obtained, which was favorable to 
azoles, with values of AR of 93%, ARR of 19%, and NNT of 
5. The value of I2 was high (68%), as the results of the stud-
ies included were contradictory. In the study by Montoya35, 
there was an impressive result in favor of azoles, while in 
the study by Aste53, no difference was detected between the 
classes. The sum of the results of two studies evaluating 
the treatment of T. cruris and T. corporis also resulted in an 
not statistically significant OR of 0.66 (95% CI; 0.28-1.54), 
however it was favorable to allylamines, with AR of 91%, 
ARR of 2%, NNT of 40, and I2 of 0%.  The global result of 
the meta-analysis (0.68 [95% CI; 0.40-1.15]) did not show 
any difference between azoles and allylamines, not evi-
dencing superiority of one class over the other.
For the outcome of sustained cure, the grouping of 
nine studies evaluating the treatment of T. pedis resulted 
in an OR statistically favorable to the use of allylamines 
(0.39 [95% CI; 0.22-0.67]), with AR of 86%, ARR of 8%, 
and NNT of 13, however with a high heterogeneity among 
the selected studies (I2 = 53%). When Ablon’s study52 was 
hypothetically removed from the meta-analysis, the het-
erogeneity became moderate and the result remained fa-
vorable to allylamines. 
Only one study comparing clotrimazole to naftifine in 
the treatment of T. versicolor was retrieved, obtaining an 
OR of 5.04 (95% CI; 1.46-17.37), AR of 73%, ARR of 38%, 
and NNT of 3, favoring the azole clotrimazole. The inter-
polation of two studies comparing azoles and allylamines 
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Figure 1A – Comparative efﬁcacy of azoles versus allylamines. Meta-analyses of azoles versus allylamines for each 
dermatomycosis under evaluation. Mycological cure at the end of treatment. 
Azoles Allylamines       Odds ratio Odds ratio
Study or subgroup Events Total Events Total Weight IV, Random, 95% CI IV, Random, 95% CI
1.1.1 Tinea pedis
Ablon, 1996a (1)52 3 14 11 33 7.8% 0.55 [0.13, 2.37]
Ablon, 1996b (2)52 3 14 10 29 7.7% 0.52 [0.12, 2.30]
Evans, 1993 (3)56 76 104 100 107 12.9% 0.19 [0.08, 0.46]
Irvine, 1990 (4)57 10 27 12 30 11.0% 0.88 [0.30, 2.57]
Leenutaphong, 1999 (5)58 15 23 12 22 9.8% 1.56 [0.47, 5.19]
Sanchez-Carazo, 1994 (6)60 14 16 26 26 2.5% 0.11 [0.00, 2.44]
Schopf, 1999 (7)61 196 199 196 198 6.0% 0.67 [0.11, 4.03]
Smith, 1990b (8)62 34 67 78 125 15.9% 0.62 [0.34, 1.13]
Subtotal (95% CI) 464 570 73.5% 0.55 [0.33, 0.92]
Total events 351 445
Heterogeneity: Tau2 = 0.17; Chi2 = 10.50; df = 7 (p = 0.16); I 2 = 33%
Test for overall effect: Z = 2.27 (p = 0.02)
1.1.2 Tinea versicolor
Aste, 1991 (9)53 19 20 20 20 2.3% 0.32 [0.01, 8.26]
Montoya, 1985c (10)35 20 22 14 26 6.8% 8,57 [1.65, 44.43]
Subtotal (95% CI) 42 46 9.0% 2.25 [0.09, 53.79]
Total events 39 34
Heterogeneity: Tau2 = 3.70; Chi2 = 3.13; df = 1 (p = 0.08); I 2 = 68%
Test for overall effect: Z = 0.50 (p = 0.62)
1.1.3 Tinea cruris and corporis
Budimulja, 1998 (11)55 84 86 87 89 5.2% 0.97 [0.13, 7.01]
Millikan, 1988 (12)59 27 40 38 49 12.2% 0.60 [0.23, 1.54]
Subtotal (95% CI) 126 138 17.4% 0.66 [0.28, 1.54]
Total events 111 125
Heterogeneity: Tau2 = 0.00; Chi2 = 0.18; df = 1 (p = 0.67); I 2 = 0%
Test for overall effect: Z = 0.97 (p = 0.33)
Total (95% CI) 632 754 100.0% 0.68 [0.40, 1.15]
Total events 501 604
Heterogeneity: Tau2 = 0.36; Chi2 = 21.06; df = 11 (p = 0.03); I 2 = 48%
Test for overall effect: Z = 1.43 (p = 0.15)
Test for subgroup differences: Chi2 = 0.81; df = 2 (p = 0.67); I 2 = 0%
(1) Oxiconazole lotion 1% once a day versus terbinaﬁne cream 1% once a day for 14 days in the treatment of T. pedis
(2) Oxiconazole lotion 1% once a day versus naftiﬁne gel 1% once a day for 14 days in the treatment of T. pedis
(3) Clotrimazole cream 1% twice a day for 28 days versus terbinaﬁne cream 1% twice a day for seven days in the treatment of T. pedis
(4) Clotrimazole cream 1% twice a day versus naftiﬁne cream 1% twice a day for 28 to 42 days in the treatment of T. pedis
(5) Miconazole cream 2% twice a day for 28 days versus terbinaﬁne cream 1% once a day for seven days in the treatment of T. pedis
(6) Bifonazole cream 1% once a day versus terbinaﬁne cream 1% once a day for 28 days in the treatment of T. pedis
(7) Clotrimazole solution 1% twice a day for 28 days versus terbinaﬁne solution 1% twice a day for seven days in the treatment of T. pedis
(8) Clotrimazole cream 1% twice a day versus naftiﬁne cream 1% once and twice a day for 28 in the treatment of T. pedis
(9) Bifonazole cream 1% twice a day for 26 days versus terbinaﬁne cream 1% twice a day for 22 days in the treatment of T. versicolor
(10) Clotrimazole cream 1% twice a day versus naftiﬁne cream 1% twice a day for 28 days in the treatment of T. versicolor
(11) Bifonazole cream 1% once a day for 21 days versus terbinaﬁne cream 1% once a day for 7 seven in the treatment of T. cruris
(12) Econazole cream 1% twice a day versus naftiﬁne cream 1% twice a day for 28 days in the treatment of T. cruris and T. corporis.
0.01 0.1 1 10 100
Favours allylamines Favours azoles
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Figure 1B – Comparative efﬁcacy of azoles versus allylamines. Meta-analyses of azoles versus allylamines for each 
dermatomycosis under evaluation. Sustained cure.
(1) Oxiconazole lotion 1% once a day versus terbinaﬁne cream 1% once a day for 14 days in the treatment of T. pedis. Follow-up for eight weeks.
(2) Oxiconazole lotion 1% once a day versus naftiﬁne gel 1% once a day for 14 days in the treatment of T. pedis. Follow-up for eight weeks.
(3) Clotrimazole cream 1% twice a day for 28 days versus terbinaﬁne cream 1% twice a day for seven days in the treatment of T. pedis. Follow-up for eight weeks.
(4) Clotrimazole cream 1% twice a day for 28 days versus terbinaﬁne cream 1% twice a day for seven days in the treatment of T. pedis. Follow-up for two weeks.
(5) Miconazole cream 2% twice a day for 28 days versus terbinaﬁne cream 1% once a day for seven days in the treatment of T. pedis. Follow-up for six weeks.
(6) Bifonazole cream 1% once a day versus terbinaﬁne cream 1% once a day for 28 days in the treatment of T. pedis. Follow-up for two weeks.
(7) Clotrimazole solution 1% twice a day for 28 days versus terbinaﬁne solution 1% twice a day for seven days in the treatment of T. pedis. Follow-up for four weeks.
(8) Clotrimazole cream 1% twice a day versus naftiﬁne cream 1% once and twice a day for 28 in the treatment of T. pedis. Follow-up for two weeks.
(9) Bifonazole cream 1% once a day versus terbinaﬁne cream 1% once a day for 14 days in the treatment of T. pedis. Follow-up for six weeks.
(10) Clotrimazole cream 1% twice a day versus naftiﬁne cream 1% twice a day for 28 days in the treatment of T. versicolor. Follow-up for two weeks.
(11) Bifonazole cream 1% once a day for 21 days versus terbinaﬁne cream 1% once a day for seven days in the treatment of T. cruris. Follow-up for ﬁve weeks.
(12) Econazole cream 1% twice a day versus naftiﬁne cream 1% twice a day for 28 days in the treatment of T. cruris and T. corporis. Follow-up for two weeks.
Azoles Allylamines       Odds ratio Odds ratio
Study or subgroup Events Total Events Total Weight IV, Random, 95% CI IV, Random, 95% CI
1.2.1 Tinea pedis
Ablon, 1996a (1)52 4 14 25 31 6.8% 0.10 [0.02, 0.41]
Ablon, 1996b (2)52 4 14 22 29 6.9% 0.13 [0.03, 0.54]
Bergstresser, 1993 (3)54 30 43 36 42 8.8% 0.38 [0.13, 1.13]
Evans, 1993 (4)56 87 104 104 107 7.8% 0.15 [0.04, 0.52]
Leenutaphong, 1999 (5)58 11 20 10 19 7.8% 1.10 [0.31, 3.88]
Sanchez-Carazo, 1994 (6)60 13 16 24 26 5.0% 0.36 [0.05, 2.44]
Schopf, 1999 (7)61 193 212 199 217 11.3% 0.92 [0.47, 1.80]
Smith, 1990b (8)62 32 55 72 101 11.2% 0.56 [0.28, 1.11]
Wahid, 1997 (9)63 30 38 36 40 7.6% 0.42 [0.11, 1.52]
Subtotal (95% CI) 516 612 73.2% 0.39 [0.22, 0.67]
Total events 404 528
Heterogeneity: Tau2 = 0.34; Chi2 = 16.98; df = 8 (p = 0.03); I 2 = 53%
Test for overall effect: Z = 3.40 (p = 0.0007)
1.2.2 Tinea versicolor
Montoya, 1985 (10)35 16 22 9 26 7.9% 5.04 [1.46, 17.37]
Subtotal (95% CI) 22 26 7.9% 5.04 [1.46, 17.37]
Total events 16 9
Heterogeneity: Not applicable
Test for overall effect: Z = 2.56 (p = 0.01)
1.2.3 Tinea cruris and corporis
Budimulja, 1998 (11)55 70 84 76 85 9.9% 0.59 [0.24, 1.45]
Millikan, 1988 (12)59 30 38 39 49 9.0% 0.96 [0.34, 2.73]
Subtotal (95% CI) 122 134 18.9% 0.73 [0.37, 1.44]
Total events 100 115
Heterogeneity: Tau2 = 0.00; Chi2 = 0.48; df = 1 (p = 0.49); I 2 = 0%
Test for overall effect: Z = 0.92 (p = 0.36)
Total (95% CI) 660 772 100.0% 0.52 [0.31, 0.89]
Total events 520 652
Heterogeneity: Tau2 = 0.54; Chi2 = 31.05; df = 11 (p = 0.001); I 2 = 65%
Test for overall effect: Z = 2.37 (p = 0.02)
Test for subgroup differences: Chi2 = 14.04; df = 2 (p = 0.0009); I 2 = 85.8%
0.01
Favours allylamines Favours azoles
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in the treatment of T. cruris and T. corporis resulted in an 
OR of 0.73 (95% CI; 0.37-1.44), not showing a statistically 
significant difference of efficacy between the classes.
However, the result was favorable to allyl-
amines, with AR of 86%, ARR of 4%, and NNT of 26, 
and I2 of 0%. The global result of the meta-analysis 
(0.52 [95% CI; 0.31-0.89]) presented a difference between 
the pharmacological classes evaluated, evidencing superi-
ority by the allylamines compared to azoles, even with the 
hypothetical withdrawal of Montoya’s study35, responsible 
for the high heterogeneity (I2 = 65%).
DISCUSSION
Dermatomycoses are the skin diseases that most com-
monly affect people worldwide, for which the first-line 
therapeutic strategy is the use of topical antifungal drugs7. 
While the popular use of these drugs prove their value 
in reducing the signs and symptoms of these infections, 
scientifically speaking, uncertainties with respect to the 
best therapy to be adopted in each case predominate, as 
a good part of the published clinical trials are small sized 
and have placebo as a comparator, and systematic review 
studies with meta-analysis are rare. Only two systematic 
reviews with meta-analyses can be found in the literature 
related to the treatment of dermatomycoses with topical 
antifungal drugs, both limited to the treatment of T. pe-
dis10-11. In this research, all azole and allylamine antifungal 
drugs were compared among themselves and with placebo 
in the treatment of any dermatomycosis.
In this systematic review, 144 articles were fully evalu-
ated, and 49 were selected to compose the meta-analyses. 
Of the 95 articles excluded, 35 failed to meet the quality 
criteria proposed by Jadad13, and 26 did not define a spe-
cific dermatomycosis diagnosis. In the aggregate, 6,044 
patients were randomly designated to receive placebo or 
one of the 13 antifungal drugs, with a predominance of 
young males.
The meta-analyses’ results demonstrate that there is 
consistent evidence of the superiority of topical antifungal 
drugs over placebo, irrespectively of the drug evaluated, 
pharmacological class, dosage form, concentration, thera-
peutic regimen adopted, duration of the treatment, diag-
nosed dermatomycosis, and efficacy outcome taken into 
consideration. These findings are consistent with those 
found in the systematic reviews by Crawford10 and Hart11; 
the superiority of all antifungal drugs compared to placebo 
in the treatment of T. pedis was detected.
Some meta-analyses presented high values of I2 (> 50%), 
indicating inconsistency in the results of the included 
studies. However, after some sensitivity analyses, includ-
ing the hypothetical removal from the meta-analysis of the 
studies considered responsible for the high heterogeneity 
mentioned, the results remained close to the ones found 
prior to the removal of the studies, maintaining their sta-
tistical significance. This shows that the variation of effects 
in the collected data upon several primary studies did not 
change the final measure of effect. These findings are com-
parable to those found in the systematic review by Craw-
ford10, whose meta-analyses also showed high heterogene-
ity among the selected studies. 
Accordingly, given the strength of the evidences found, 
clinical trials controlled by placebo evaluating topical an-
tifungal drugs in the treatment of dermatomycoses are no 
longer justifiable; only clinical trials comparing two active 
treatments are reccomended.  Crawford et al., in 2008, 
published an article confirming that there is enough evi-
dence to recommend the abandonment of trials controlled 
by placebo evaluating topical antifungal drugs in the treat-
ment of T. pedis64.
With respect to the comparisons made between anti-
fungal classes, in Crawford’s study, 11 studies comparing 
azoles with allylamines were selected and the result found 
was statistically favorable to allylamines, with difference 
between the classes detected in the period of six weeks fol-
lowing the beginning of the treatment and maintained in 
more extensive follow-up periods10.
The same result favoring the use of allylamines was ob-
tained in the study developed by Hart in 1999; however, a 
publication bias was detected. Of the 12 studies that inte-
grated the meta-analysis, eight favored the allylamines, all 
published in English. The four additional studies did not 
show significant differences between the evaluated classes, 
all published in other languages11.
In this research, for the outcome of mycological cure 
at the end of treatment, a statistically significant difference 
was found between the classes, favoring allylamines only 
in the treatment of T. pedis, which is consistent with the 
findings of Hart and Crawford10-11. When the results ob-
tained for each dermatomycosis were aggregated, no dif-
ference of efficacy between the classes was identified. 
For the outcome of sustained cure, once again allyl-
amines were better compared to azoles in the treatment 
of T. pedis. For the treatment of T. versicolor, the azole 
clotrimazole was statistically better than naftifine but this 
result arose from a single clinical trial. The global result of 
the meta-analysis was statistically favorable to allylamines, 
even after sensitivity analyses. This superiority of the al-
lylamines in the general result is due to the greater empha-
sis on studies involving T. pedis in the total meta-analysis. 
With the currently available evidence, it is not possible to 
state the superiority of allylamines with respect to azoles 
for other dermatomycoses.
The impressive maintenance of the cure after the end 
of the therapy can be supported by the lipophilic and kera-
tinophilic characteristics of allylamines, enabling them to 
remain pharmacologically active in the skin even after the 
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suspension of the treatment. The fungicidal mechanism of 
action of allylamines, opposed to the fungistatic mecha-
nism of the azole drugs, may also have contributed to bet-
ter responses obtained with the usage of this class4.
Due to the difference of cost between azole and allyl-
amine drugs, the incorporation of economic outcomes 
into the systematic review, such as the performance of 
cost-effectiveness analyses, shall define the therapeutic 
option that presents the best clinical results per currency 
unit invested, representing the most effective alternative to 
each clinical condition taken into consideration.
CONCLUSION
The results found show consistent evidence of the supe-
riority of antifungal drugs with respect to placebo in the 
treatment of any clinical form of dermatomycosis. Through 
meta-analyses of direct comparisons, a difference between 
azoles and allylamines in the treatment of T. pedis was de-
tected; the result was favorable to allylamines for both cure 
outcomes. For the outcome of sustained cure, the global 
result of the meta-analysis shows that allylamines are bet-
ter than azoles, nevertheless, the results have a high level 
of evidence only for T. pedis. There are no clinical trials of 
good methodological quality comparing azoles and allyl-
amines in the treatment of cutaneous candidiasis. 
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